NCT02358473View on ClinicalTrials.gov

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Non-Small Cell Lung Cancer
Interventions
BIOLOGICAL

mogamulizumab

Mogamulizumab will be administered by IV infusion.

DRUG

Docetaxel

Docetaxel will be administered by IV infusion.

Trial Locations (5)

21231

John Hopkins University School of Medicine, Baltimore

44718

Gabrail Cancer Center Research, Canton

47905

Horizon Oncology, Lafayette

77025

MD Anderson, Houston

78229

Cancer Therapy and Research Center, San Antonio

Sponsors

Lead Sponsor

Kyowa Kirin, Inc.
All Listed Sponsors
lead

Kyowa Kirin, Inc.

INDUSTRY

NCT02358473 - Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter